Precision Epigenomics announced the results of a new study showing EPISEEK outperforms alternative liquid biopsy tests across the board.
Public source
Publisher name
Public post
Today, I am proud to announce the results of our new study. If you are evaluating MCED solutions for your practice or health system, the data are clear-cut: EPISEEK is o…
Company
Precision Epigenomics
Advanced Solutions to Early Cancer Diagnostics
- Industry
- Medical and Diagnostic Laboratories
- Location
- Tucson, US
- Company size
- 11–50 employees
About Precision Epigenomics
Advanced Solutions to Early Cancer Diagnostics
See moreLatest activity
Latest activity from Precision Epigenomics
7 signals
Research & Knowledge
Precision Epigenomics released the results of its most recent data on the EPISEEK multi-cancer early detection test.
Presence & Recognition
Precision Epigenomics honors all First Responders at the FRI 2026 event.
Research & Knowledge
Precision Epigenomics published the results of a new study showing EPISEEK outperforms alternative liquid biopsy tests across the board in sensitivity, specificity, and turnaround time.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Biocartis
Biocartis published a study in the International Journal of Molecular Sciences testing the Idylla IDH1-2 assay across 106 patient samples spanning glioma, cholangiocarcinoma, chondrosarcoma, breast cancer, and acute myeloid leukemia.
Research & Knowledge
Helio Genomics
Helio Genomics published results from a prospective, blinded, multicenter CLiMB study demonstrating that HelioLiver blood-based test showed higher sensitivity for hepatocellular carcinoma detection than ultrasound at 47.8% vs. 28.3%
Research & Knowledge
Mercy BioAnalytics, Inc.
Mercy BioAnalytics, Inc. published a peer-reviewed publication in Gynecologic Oncology demonstrating the potential of their EVP-based blood test to detect early-stage high-grade serous ovarian cancer with 89% sensitivity and 98% specificity in preclinical UKCTOCS samples.
Research & Knowledge
Break Through Cancer
Break Through Cancer published a study in PNAS by the Eradicating Measurable Residual Disease in AML TeamLab team developing a personalized blood test that tracks up to 96 mutations specific to an individual patient’s leukemia.
Research & Knowledge
Cizzle Bio, Inc.